Predicted biological activity of intravitreal VEGF Trap
- 1Mayo Clinic College of Medicine, Jacksonville, Florida, USA
- 2Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA
- Dr M W Stewart, Department of Ophthalmology, 4500 San Pablo Rd, Jacksonville, FL 32224, USA; stewart.michael{at}mayo.edu
- Accepted 11 February 2008
- Published Online First 20 March 2008
Abstract
Aim: To compare the intravitreal binding activity of VEGF Trap with that of ranibizumab against vascular endothelial growth factor (VEGF) using a time-dependent and dose-dependent mathematical model.
Methods: Intravitreal half-lives and relative equimolar VEGF-binding activities of VEGF Trap and ranibizumab were incorporated into a first-order decay model. Time-dependent VEGF Trap activities (relative to ranibizumab) for different initial doses (0.5, 1.15, 2 and 4 mg) were calculated and plotted.
Results: Seventy-nine days after a single VEGF Trap (1.15 mg) injection, the intravitreal VEGF-binding activity would be comparable to ranibizumab at 30 days. After injection of 0.5, 2 and 4 mg VEGF Trap, the intravitreal VEGF-binding activities (comparable to ranibizumab at 30 days) would occur at 73, 83 and 87 days, respectively
Conclusion: On the basis of this mathematical model, VEGF Trap maintains significant intravitreal VEGF-binding activity for 10–12 weeks after a single injection.
Footnotes
-
Competing interests: None.
